HHHaruka Hamanoue

Haruka Hamanoue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haruka Hamanoue has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Maternal copy number variations detected by noninvasive prenatal testing in Japanese women

    by Kaku Masuda, Hiroyuki Mishima, Koh-Ichiro Yoshiura, Yuriko Kitajima, Shoko Miura, Yuri Hasegawa, Kiyotake Ichizuka, Makiko Tominaga, Reina Komatsu, Tetsuro Kondo, et al.

    Non-invasive prenatal testing (NIPT) is a screening method that detects fetal chromosomal trisomies from cell-free DNA in maternal blood. Because NIPT uses whole-genome sequencing with next-generation sequencing for data processing, it can also detect maternal genomic information. Although most copy number variations (CNVs) are benign, some have been reported to be associated with pathological phenotypes and are attracting increasing attention. However, most CNV studies have been conducted in Western populations, and large-scale studies in Japanese cohorts remain scarce. This study represents the first multicenter, large-scale cohort investigation of maternal CNVs in Japanese pregnant women. We analyzed 46,082 participants to establish a reliable threshold for maternal CNV detection and to evaluate their clinical significance. Maternal CNVs were validated using array comparative genomic hybridization, and receiver operating characteristic curve analysis identified 0.8 Mbp as the minimum threshold achieving 100% specificity. Applying this criterion, maternal CNVs were identified in 2907 cases (6.3%), with the most frequent being a duplication at chr8: 3,842,478-6,092,478 (hg38, allele frequency 2.67%). Comparison with public genomic databases, including the Tohoku Medical Megabank Organization (ToMMo) and the Genome Aggregation Database (gnomAD), confirmed that all CNVs detected in this study had been previously reported, with particularly high concordance in ToMMo. Notably, several very rare CNVs were also identified. These findings demonstrate that NIPT can reliably detect maternal CNVs ≥0.8 Mbp, which appear to represent benign genomic variants that are unlikely to affect fertility or early miscarriage.

  • Open Access

    Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers

    by Ryosuke Jikuya, Todd A. Johnson, Erika Muraoka, Go Noguchi, Shigekatsu Maekawa, Wataru Obara, Kazuyuki Numakura, Tomonori Habuchi, Kazuhiro Maejima, Shota Sasagawa, et al.

    There is a great unmet medical need for development of molecularly characterizing modalities to assist in the complex classification of rare kidney cancers, some of which are diagnosed as unclassified renal cell carcinoma (unclassified RCC) due to complex histology. Here we show utility of the comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers. Whereas whole genome sequencing (WGS) of 52 rare kidney cancers identifies very few clinically significant variants in a subset of cases, unsupervised clustering results of RNA-seq data from 219 renal tumors including 140 rare kidney cancers are largely consistent with the histological classification based on WHO2022 classification. Additionally, the comparative transcriptome atlas may provide an opportunity to define the molecular characteristics of unclassified RCC and might predict patient outcome. These findings support the comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers.


  • Perinatal outcomes of fetal CNVs detected by genome-wide non-invasive prenatal testing in Japan

    by Yuka Yamashita, Nahoko Shirato, Tatsuko Ishii, Mikiko Izumi, Kiyotake Ichizuka, Makiko Tominaga, Reina Komatsu, Tetsuro Kondo, Seiji Wada, Haruhiko Sago, et al.

    Non-invasive prenatal testing (NIPT) enables the screening of fetal chromosomal abnormalities by analyzing cell-free DNA (cfDNA) in maternal blood. Recent technological advancements have expanded its applications to the detection of copy number variations (CNVs). However, the clinical utility of CNV detection remains unclear. We aimed to investigate the association between fetal CNVs detected by genome-wide NIPT and perinatal outcomes in a large cohort in Japan. This retrospective cohort study included 46,082 patients who underwent NIPT at certified facilities in Japan between January 2015 and September 2021. Genome-wide NIPT was performed using massively parallel sequencing to detect fetal CNVs exceeding 7 Mb. Despite their small size, well-characterized microdeletions, such as 22q11.2 were included. From 46,082 patients with NIPT results, 30,373 cases with known birth outcomes were extracted, and cases with fetal CNV were included in the analysis. Fetal CNVs were detected in 66 patients (0.2%). Adverse outcomes, including miscarriage, growth restriction, and structural abnormalities, were observed in 14 of the 66 cases (21.2%). Pathogenic CNVs were frequently detected even in the 52 cases (78.8%) with favorable outcomes. Genome-wide NIPT may assist in the diagnosis of cases with structural abnormalities when combined with confirmatory testing. Our findings demonstrate that pathogenic CNVs are also detected in a substantial number of structurally normal fetuses with favorable short-term outcomes. This discordance presents a significant challenge for prenatal counseling. The clinical significance of the findings should be clarified through confirmatory testing of CNV cases and the accumulation of data from long-term follow-up studies.


  • Open Access

    Radiation‐induced congenital malformations in Fukushima after the Fukushima Daiichi Nuclear Disaster

    by Shinya Kondo, Toshiyuki Itai, Chika Akamatsu, Shin Saitoh, Akiko Iwata, Haruka Hamanoue, Fumiki Hirahara, Isamu Ishiwata, Satoru Shinoda, Etsuko Miyagi, et al.

    The Fukushima Daiichi Nuclear Disaster (FDND) occurred in 2011, which occurred after the Great East Japan Earthquake. However, how the incidence of radiation‐induced malformations in Fukushima has been affected by FDND remains to be elucidated. To address this, we analyzed birth data from Fukushima and other areas in Japan from the International Clearinghouse for Birth Defects Surveillance and Research Japan Center, including information on birth defects between January 2010 and December 2022. Among the registered birth defects, microcephaly, microphthalmia, and neural tube defects were classified as radiation‐induced malformations. Our study included 90 433 births in Fukushima, accounting for 52.6% of all births. Among these, birth defects were observed in 1376 (1.52%) births, of which 28 (0.031%) were diagnosed with radiation‐induced malformations. With regard to other areas in Japan, 1 323 391 births, which accounted for 10.9% of all births, were registered; births with birth defects and radiation‐induced malformations were observed in 37 490 (3.67%) and 889 (0.067%), respectively. Because sampling bias was suspected, we compared the rates of radiation‐induced malformations in Fukushima and other areas in Japan by adjusting the incidence in Fukushima with the incidences of ventricular septal defects in both areas. However, there was no statistically significant difference between them. Our results, which covered the largest number of births in Fukushima, did not find a significant increase in the incidence of radiation‐induced malformations in Fukushima since FDND.

  • Inconsistent embryo selection across polygenic score methods

    by Shinichi Namba, Masato Akiyama, Haruka Hamanoue, Kazuto Kato, Minae Kawashima, Itaru Kushima, Koichi Matsuda, Masahiro Nakatochi, Soichi Ogishima, Kyuto Sonehara, et al.


  • Open Access

    Rapid and comprehensive diagnostic method for repeat expansion diseases using nanopore sequencing

    by Satoko Miyatake, Eriko Koshimizu, Atsushi Fujita, Hiroshi Doi, Masaki Okubo, Taishi Wada, Kohei Hamanaka, Naohisa Ueda, Hitaru Kishida, Gaku Minase, et al.

    We developed a diagnostic method for repeat expansion diseases using a long-read sequencer to improve currently available, low throughput diagnostic methods. We employed the real-time target enrichment system of the nanopore GridION sequencer using the adaptive sampling option, in which software-based target assignment is available without prior sample enrichment, and built an analysis pipeline that prioritized the disease-causing loci. Twenty-two patients with various neurological and neuromuscular diseases, including 12 with genetically diagnosed repeat expansion diseases and 10 manifesting cerebellar ataxia, but without genetic diagnosis, were analyzed. We first sequenced the 12 molecularly diagnosed patients and accurately confirmed expanded repeats in all with uniform depth of coverage across the loci. Next, we applied our method and a conventional method to 10 molecularly undiagnosed patients. Our method corrected inaccurate diagnoses of two patients by the conventional method. Our method is superior to conventional diagnostic methods in terms of speed, accuracy, and comprehensiveness.